Trial Profile

A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enasidenib (Primary) ; Azacitidine
Indications Myelodysplastic syndromes
Focus Therapeutic Use
Acronyms GFM-IDEAL-Study

Most Recent Events

18 Apr 2024 Planned End Date changed from 18 Feb 2023 to 18 Mar 2026.
18 Apr 2024 Status changed from recruiting to active, no longer recruiting.
14 Dec 2021 Interim Results (At data cut off 6/15/2021, n=26)presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com